Xolair (Omalizumab)

Xolair is a medicine used to treat severe allergic asthma. It works by blocking the action of IgE, a protein that triggers allergic reactions. This helps prevent asthma attacks and reduces the need for other asthma medications.

Brand names:Xolair
Medication

What people taking Xolair (Omalizumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Xolair (Omalizumab) for Food Hypersensitivity?

NameHow it went

About Xolair (Omalizumab)

What It's For

Omalizumab, sold as Xolair, is an injected prescription medicine for allergic conditions that standard treatment has not controlled well enough. It is not a first step: each approved use applies to people who still have symptoms despite the usual treatments. In the US it is approved for four conditions. The first is moderate to severe persistent asthma in people 6 and older whose asthma is linked to a year-round airborne allergen (confirmed by a skin or blood test) and is not controlled by inhaled corticosteroids, the daily steroid inhalers used to calm airway inflammation. The second is chronic rhinosinusitis with nasal polyps, long-lasting inflammation of the nose and sinuses with soft, noncancerous growths, in adults whose symptoms continue despite steroid nasal sprays. The third is chronic spontaneous urticaria, hives and itching that keep returning for no identifiable reason, in people 12 and older who still have symptoms on antihistamines. The fourth is food allergy in people 1 year and older, where omalizumab lowers the chance of a serious reaction after accidentally eating a food they are allergic to. It is used alongside continued avoidance of those foods, not in place of it. Omlyclo (omalizumab-igec) is a biosimilar to Xolair: a closely matching version made by a different company, approved for the same four uses and available in the US since October 2026.

How It Works

IgE (immunoglobulin E) is the antibody the immune system makes against allergens such as pollen, dust or a food protein. IgE sits on the surface of immune cells called mast cells and basophils, found in the airways, skin and gut. When the allergen meets that IgE, the cells release chemicals that cause wheezing, swelling, itching and hives. Omalizumab is a monoclonal antibody, a laboratory-made antibody designed to attach to one target. It binds IgE circulating in the blood so that IgE can no longer lock onto those immune cells. Over time the cells also carry fewer IgE receptors, so allergens trigger less of a reaction. In chronic hives, omalizumab lowers free IgE in the same way, but exactly why that clears hives is not fully understood. Because it works by gradually dampening the allergic response rather than opening the airways or reversing a reaction, it does not act quickly. It is a maintenance treatment, not a rescue medicine.

Dosage & Administration

Omalizumab is injected under the skin, usually every 2 or 4 weeks. For asthma, nasal polyps and food allergy, the dose and schedule are set from a blood test for total IgE taken before treatment starts, together with body weight, and range from 75 mg to 600 mg per dose. Larger doses are split into two or more injections given at least an inch apart. Total IgE in the blood rises during treatment and stays high for up to a year after stopping, so retesting it does not guide the dose, though a significant change in weight can. For chronic hives, the dose is fixed at 150 mg or 300 mg every 4 weeks, without an IgE test. Treatment begins in a clinic or office, where staff watch for an allergic reaction after each injection. After at least three supervised doses without a reaction, the prescriber may allow injections at home with a prefilled syringe or autoinjector pen. That option is generally for people with no past anaphylaxis to other medicines, biologics or other triggers (for food allergy, past reactions to food do not rule it out), and who, or whose caregiver, can recognize and treat anaphylaxis. Teenagers 12 and older may inject under adult supervision; children 1 to 11 receive the prefilled syringe from a caregiver, and the autoinjector is not for children under 12. Injections go into the thigh or abdomen, or the outer upper arm when someone else gives them. The powder form in vials is prepared and injected only by healthcare staff.

Side Effects

The most common side effect is an injection site reaction: bruising, redness, warmth, stinging, itching or swelling where the needle went in. These usually appear within an hour, fade within about a week and tend to become less frequent with later doses. Other common effects depend on the condition and age group and include headache, joint pain, tiredness, nasal and throat infections, and fever in children. The most important risk is anaphylaxis, a severe whole-body allergic reaction, which carries the drug's boxed warning (the most prominent warning the US Food and Drug Administration requires). It is uncommon, affecting roughly 1 or 2 in 1,000 people treated, and most cases occur within the first three doses, often within two hours. It can also happen after the first dose, more than a year into treatment, or days after an injection. People who have had anaphylaxis to foods, medicines or other causes face a higher risk. Get emergency care right away for trouble breathing, wheezing or chest tightness; dizziness, fainting or a rapid or weak heartbeat; swelling of the throat or tongue, a hoarse voice or trouble swallowing; or hives and flushing along with any of these. A less common reaction combines fever, joint pain, rash and swollen glands 1 to 5 days after an injection. Tell the prescriber if this happens, since it usually means omalizumab should be stopped.

Interactions & Warnings

Omalizumab is not a treatment for an asthma attack or an allergic reaction that is already happening, including anaphylaxis. A rescue inhaler and the food allergy emergency plan from the care team are still needed. Do not stop or lower other asthma, sinus, hives or food allergy medicines, or allergy shots, unless the prescriber says to. Steroid medicines in particular, whether tablets or inhalers, should be reduced gradually under supervision rather than stopped abruptly once omalizumab starts. Rarely, people with asthma have developed serious inflammation of the blood vessels with high levels of eosinophils, a type of white blood cell, usually while their steroid tablets were being reduced. It is not known whether omalizumab causes this. Contact the prescriber right away about a new rash, shortness of breath, chest pain, or pins and needles or numbness in the arms or legs. No formal drug interaction studies have been done, and combinations with allergy shots or with immune-suppressing medicines for hives have not been studied. Early trials found slightly more cancers in people taking omalizumab than in those who were not; a later five-year study found similar rates, but a risk cannot be fully ruled out, so a history of cancer is worth discussing. People who live in or travel to areas where intestinal worm infections are common may be more likely to pick one up during treatment. In a pregnancy registry, omalizumab was not linked to more birth defects or miscarriages. Babies were more often born at low weight, but their mothers also had more severe asthma, which can itself affect pregnancy, so the cause is unclear. Anyone pregnant, planning pregnancy or breastfeeding should weigh these points with the prescriber, along with the risks of poorly controlled asthma.

What to Expect

Benefits build over weeks to months rather than appearing after the first injection. How much omalizumab helps differs by condition and from person to person. In asthma trials, people taking it had fewer flare-ups serious enough to need steroid tablets or a higher inhaled steroid dose. In nasal polyp trials, congestion and polyp size improved more than with placebo, with differences visible by the first check at four weeks. In a 12-week trial in chronic hives, about a third of people on the 300 mg dose were completely free of itch and hives, compared with about 1 in 11 on placebo; many others improved partly. For food allergy, the goal is a higher reaction threshold, not a cure. In a trial of children with several food allergies, about two thirds of those on omalizumab could eat a single dose of 600 mg of peanut protein after about four months without significant symptoms, compared with 7% on placebo. That margin can make a small accidental exposure less dangerous, but people still avoid their trigger foods and keep their emergency plan. Treatment usually means an injection visit or a home dose every 2 to 4 weeks for as long as it keeps helping. The prescriber reassesses the need for treatment periodically, and the right duration for food allergy and chronic hives has not been established. If asthma stays uncontrolled or gets worse after starting omalizumab, contact the care team rather than waiting for the next injection.

Questions to Ask Your Doctor

  1. 1.What would a good response look like for my condition, and when will we decide whether omalizumab is working?
  2. 2.How does omalizumab compare with other biologic injections or treatments I could try instead?
  3. 3.How long will I be observed after injections, and would I be a candidate for home injections later?
  4. 4.Which of my current medicines, including steroids, might be reduced over time, and how would we do that safely?
  5. 5.If I stop treatment, what would happen to my symptoms, and how would we plan for it?

Last reviewed • Oct 2026

Educational content, not medical advice.